Article Sidebar

PDF
Date Published: 21/04/2022
Abstract Views: 286
Views PDF: 135
DOI: https://doi.org/10.51298/vmj.v511i2.2151
Issue
Vol. 511 No. 2 (2022)
Section
Các bài báo
How to Cite
Lê Huy, T. ., & Đình Anh, T. . (2022). EVALUATION OF TREATMENT RESULTS FOR STAGE IV NON-SMALL CELL LUNG CANCER WITH NAVELBIN METRONOMIC AT HANOI MEDICAL UNIVERSITY HOSPITAL. Vietnam Medical Journal, 511(2). https://doi.org/10.51298/vmj.v511i2.2151

EVALUATION OF TREATMENT RESULTS FOR STAGE IV NON-SMALL CELL LUNG CANCER WITH NAVELBIN METRONOMIC AT HANOI MEDICAL UNIVERSITY HOSPITAL

Trịnh Lê Huy1,2,, Trần Đình Anh2
1 Hanoi Medical University
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objective: To evaluate the treatment results of Navelbine metronomic in stage IV non-small cell lung cancer (NSCLC). Patients and methods: Retrospective, descriptive study on30stage IV non-small cell lung cancer patients treated with Navelbin metronomic regimen at the Department of Oncology and Palliative Care, Hanoi Medical University Hospital from January 2014 to November 2020. Results: The mean age was67 years old, ratio male/female=6:1. All of the patients have performance status (PS) 2-3, in which PS3 accounted for 60%. Among 30 patients, 5 patients (16.7%) received first-line treatment, and 25 patients (83.3%) received second-line treatment. Most of the patients had underlying medical conditions, in which hypertension accounted for the highest rate (43.3%). The response rate was 36.7%, the PS was a statistically significant predictor of response (P<0.05). Median progression-free survival (PFS) was 8 months with first-line treatment and 6 months with second-line treatment (P>0.05). The rate of toxicity was low, mainly at a mild level (grade 1/2), the most common side effect was anemia with a rate of 30%, no patients had grade 3/4.Conclusion: Navelbine metronomic was safe and effective in stage IV NSCLC patients with poor performance status (PS 2-3) and comorbidities.

Article Details

Keywords

non-small cell lung cancer, Navelbin, Metronomic

References

1. H. Sung, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a Cancer Journal for Clinicians. 2021;71(3),pp.209-249.
2. Non-Small Cell Lung Cancercollaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysisusing updated data on individual patientsfrom 52 randomized clinical trials.BMJ. 2005;311(7010), pp.899-909.
3. A. Camerini, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial), BMC Cancer. 2015;15,DOI: 10.1186/s12885-015-1354-2.
4. P.A. Bunn. Chemotherapy foradvanced non-small-cell lung cancer: who,what, when, why?,J. Clin. Oncol. 2002;20, pp.23s-33s.
5. M. D’Ascanio, et al. Metronomic chemotherapy with vinorelbine produces clinical benefit and low toxicity in frail elderly patients affected by advanced non-small cell lung cancer, Biomed Research International. 2018;DOI: 10.1155/2018/6278403.
6. G.L. Banna, et al. Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy, Anticancer Research. 2018; 38(6),pp.3689-3697.
7. Phạm Văn Trường (2013), Đánh giá hiệu quả hóa trị phác đồ vinorelbine-cisplatin trong ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV tại Bệnh viện K, Luận văn thạc sĩ y học, Trường Đại học Y Hà Nội.